



## **WANG Ying**

### **Partner**

### **Areas of Practice**



Ms. Wang focuses her practice on patent and technology transaction areas. Ms. Wang had been working consecutively in LungTin IP firm, the Patent and Licensing Department of Novozymes China and later in AnJie Law Firm. She joined Lifang & Partners in June 2021.

Ms. Wang mainly works for high-tech companies, especially those in the fields of pharma, biotechnology, chemistry and chemical engineering. She represents clients in patent invalidation and infringement litigation. As a legal counsel to a number of biopharmaceutical companies, she helps the clients with patent strategy development, establishment of enterprise IP system, patent prosecution, and provides clients with patent validity analysis, FTO analysis, etc.

In the past few years, Ms. Wang has represented many domestic companies in the negotiation of technology licensing and R&D collaboration with foreign companies and universities, covering the fields of gene editing, drug development, medical devices, cosmetics, semiconductor and other technical fields, and helped clients draft and review contracts.

In addition to China patent practice, Ms. Wang also has a deep understanding and practice in major foreign countries such as the United States, Europe and India, and can provide clients with a global perspective on patent protection strategies. During her nine years' working period as an inhouse IP counsel, Ms. Wang had worked on global IP issues for several business units, including managing a series of European patent opposition and appeal cases between Novozymes and its competitors, and participating in licensing negotiations to settle Novozymes' global IP disputes. Ms. Wang had also worked as a team member in a plenty of R&D projects, with rich experiences in patent landscape analysis, design around and IP risk management.

### **Representative Matters**

- Represented a Chinese Biotech company in license negotiation with Broad Institute on CRISPR-Cas9 patent portfolios, and reviewed its agreement;
- Represented Cure Genetics Co. Ltd on its R&D collaboration and licensing negotiation with Boehringer Ingelheim and reviewed its agreement;



- Represented a Chinese Biotech company on a R&D collaboration negotiation for CAR-T and drafted agreement;
- Advised Sinocompound Catalysts Co. Ltd on technology licensing from MIT and drafted sub-license agreement;
- Advised Bluepha Co. Ltd on its technology collaboration with Sinochem Group;
- Represented a start-up biopharma company on acquiring new drug technology;
- Represent a Japanese cosmetic company on technology licensing with a Chinese company and reviewed its agreement;
- Provided opinions on IP strategy of a pharmaceutical project for Shanghai Chengwei Changqing Equity Investment Management Company;
- Represented a U.S. company for IP due diligence in a M&A deal in China;
- Drafted the book of “IP Guideline for outbound investment” for Shanghai Municipal Commission of Commerce (including patent, trademark, copyright, trade secret, IP due diligence and IP protection for trade fairs);
- Patent infringement analysis for a series of design patents, patent infringement analysis for medical instrument and biopharma patents;
- Provided patent layout consultation, patent infringement analysis and patent design around analysis for Wanhua Chemical Co.,
- Representing Rhodia Chemical for its patent infringement litigation against Zibo Jiahua Advanced Materials Resources Co.,
- Representing Personal Genomics Taiwan INC., against Pacific Bioscience Company in the case of patent infringement and invalidation related to gene sequencing;
- Representing BISSEL in a series of patent infringement and invalidation cases against TINECO related to floor cleaning machine;
- Advised a European pharma company on technology transaction dispute with a Chinese company, including litigation strategy related to trade secret infringement, IP ownership dispute and HKIAC Arbitration;



- Represented Philip Morris on a design patent infringement lawsuit against a Chinese company;
- Represented FRX Polymers, Inc on administrative litigation for patent reexamination;
- Represented Novozymes on a patent infringement litigation against local enzymes companies;
- Represented Novozymes on managing a series of EP opposition/appeal cases against Genencor and AB Enzymes;
- Represented Novozymes on managing patent invalidation cases in China.

#### **Professional Affiliations**

- Member of All China Lawyers Association
- Member of All-China Patent Agents Association
- Member of LESI (Licensing Executives Society International)
- Advisory Expert for National Overseas IP Dispute Settlement

#### **Awards**

- Recommended Patent Transactions Individual, IAM Patent 1000, 2024
- Recommended Intellectual Property Lawyer, The Legal 500, 2017

#### **Publications/Speeches**

- “New development of patent protection for improved new drugs”, May 2023, Wolters Kluwer
- “China Patent: Data supplementation for chemical and biotech patents in China” March 2018, Managing Intellectual Property.
- International Comparative Legal Guide: Patents 2018 (8th Edition) published in September 2017 <https://iclg.com/practice-areas/patents-laws-and-regulations/china>
- “China Patent: Patent Enforcement at Trade Fairs” October 2016, Managing Intellectual Property.
- “China Patent: Patent Law Amendments Cause Hope and Questions” February 2016, Managing Intellectual Property.



- Chinese Speech: "Analysis of IP Terms and Other related Terms in Technology Transfer" October 19, 2023, the 8th Pharmaceutical Intellectual Property Summit, Shanghai
- Chinese Speech: "Key Legal Issues in Technology Licensing and R&D Cooperation" May 2023, Zhongguancun Intellectual Property Forum, Beijing
- Chinese Speech: "IP Due Diligence Priorities and Business Implications in Different Scenarios", September 2022, 7th Pharmaceutical IP Summit, Suzhou
- Chinese Speech: "Risk Management in Patent Freedom to Analysis (FTO) for Enterprises Going Global", November 2021, organized by the National Overseas Intellectual Property Response Guidance Center, online
- Chinese Speech: "Drug Patent Linking and Patent Extension", September 30, 2021, China Biological and Chemical Pharmaceutical Industry Conference, Suzhou
- Chinese Speech: "IP due diligence in the listing, investment, M&A of pharmaceutical enterprises", Asia-Pacific Biomedical Cooperation Summit, Shanghai, January 21, 2021
- Chinese Speech: "Main legal points of technology licensing and R&D cooperation in biopharmaceutical field", L-Counsel, webinar, October 10, 2020
- Chinese Speech: "Chinese bio/pharma patents: A review from validity perspective", The 2nd Pharmaceutical Intellectual Property Summit, December 7, 2017, Shanghai
- Chinese Speech: "Patent strategy - empowering pharmaceutical R&D", Asian Pharmaceutical Research and Development Leaders Summit, April 11, 2017, Shanghai
- English Speech: "Life science focus: how to balance R&D resource and patent", China International IP Forum organized by Managing Intellectual Property, June 12, 2014, Beijing
- English Speech: "Freedom to Operate Analysis", "Patent invalidation in China", 5th Advanced China IP Counsel Forum organized by American Conference Institute, April 17, 2013, Shanghai

## **Education**

- LLM, Temple University,
- M.Sc. in Biochemistry, Tsinghua University,
- B.Sc. in Biological Science and Biotechnology, Zhejiang University,



**LIFANG & PARTNERS**  
立 方 律 师 事 务 所

12F, Shun Tak Tower  
1 Xiangheyuan Street  
Dongcheng District, Beijing 100028

Tel: +86 10 6409 6099  
Fax: +86 10 6409 6260 / 6409 6261  
[www.lifanglaw.com](http://www.lifanglaw.com)

## **Qualifications**

- China Licensed Lawyer
- China Licensed Patent Attorney

## **Working Languages**

- Mandarin Chinese
- English